Bicycle Therapeutics (BCYC)
(Delayed Data from NSDQ)
$7.56 USD
-0.30 (-3.82%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $7.54 -0.02 (-0.26%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Bicycle Therapeutics PLC Sponsored ADR's return on equity, or ROE, is -25.54% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.08%. While this shows that BCYC has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
BCYC 7.56 -0.30(-3.82%)
Will BCYC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BCYC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCYC
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?
Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock?
BCYC: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Bicycle Therapeutics (BCYC) a New Buy Stock
Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?
Other News for BCYC
Bicycle Therapeutics (BCYC) Target Price Reduced by RBC Capital | BCYC Stock News
Bicycle Therapeutics (BCYC) Price Target Reduced by RBC Capital | BCYC Stock News
Bicycle Therapeutics price target lowered by $7 at RBC Capital, here's why
Demystifying Bicycle Therapeutics: Insights From 7 Analyst Reviews
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BCYC ...